Drug Trial Radar · NCT02437591
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Aug 13, 2015
Primary completion
May 12, 2016
Study completion Oct 24, 2016
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the plasma pharmacokinetics (PK) of fidaxomicin (FDX) and primary metabolite OP-1118 in Subjects with Inflammatory Bowel Disease (IBD) and C. difficile Infection (CDI). This study will also compare CDI clinical response to the microbiological response in terms of magnitude of reduction of C. difficile total viable count and spore count during treatment with FDX and if achieved; the time to microbial eradication; determine time to negative CDI toxin assay in stool specimens during treatment with FDX; assess the stool concentrations of FDX and metabolite OP-1118 throughout therapy; assess the length of hospital stay, readmissions and resource utilization for IBD patients receiving FDX; record the incidence and severity of Adverse Events (AEs) and document the impact of treatment on Quality of Life as measured by the changes in Short Inflammatory Bowel Disease Questionnaire (IBDQ) score.
Conditions
- Inflammatory Bowel Disease (IBD)
- Clostridium Difficile Infection (CDI)
Interventions
fidaxomicinDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameter of fidaxomicin: Maximum plasma concentration (Cmax)Time frame: Day 1, Day 5 and Day 10
- Pharmacokinetic parameter of OP-1118: Maximum plasma concentration (Cmax)Time frame: Day 1, Day 5 and Day 10
- Pharmacokinetic parameter of fidaxomicin: Area under the curve from 0 to 12 hrs (AUC12)Time frame: Day 1
- Pharmacokinetic parameter of OP-1118: Area under the curve from 0 to 12 hrs (AUC12)Time frame: Day 1
- Pharmacokinetic parameter of fidaxomicin and OP-1118: Metabolite to Parent Ratio (MPR)Time frame: Day 1
- Pharmacokinetic parameter of fidaxomicin: Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)Time frame: Day 5 and Day 10
- Pharmacokinetic parameter of OP-1118: Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)Time frame: Day 5 and Day 10
- Pharmacokinetic parameter of fidaxomicin: The time after dosing when Cmax occurs (tmax)Time frame: Day 1, Day 5 and Day 10
- Pharmacokinetic parameter of OP-1118: The time after dosing when Cmax occurs (tmax)Time frame: Day 1, Day 5 and Day 10
- Pharmacokinetic parameter of fidaxomicin: Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)Time frame: Day 5 and Day 10
- Pharmacokinetic parameter of OP-1118: Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)Time frame: Day 5 and Day 10
- Pharmacokinetic parameter of fidaxomicin: Concentration immediately prior to dosing at multiple dosing (Ctrough)Time frame: Day 5 and Day 10
- Pharmacokinetic parameter of OP-1118: Concentration immediately prior to dosing at multiple dosing (Ctrough)Time frame: Day 5 and Day 10
Locations
12 sites in 7 countries. Site status is shown where the registry gives one.
Site AT43001
Graz, Austria
Site FR33002
Clichy, France
Site FR33001
Paris, France
Site GR30004
Athens, Greece
Site IT39003
Padova, Italy
Site IT39001
Roma, Italy
Site PL48002
Warsaw, Poland
Site PL48003
Warsaw, Poland
Site RU70003
Moscow, Russia
Site RU70002
Moscow, Russia
Site RU70001
Saint Petersburg, Russia
Site GB44002
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.